Connect with us

CBD

CBD News: Another hemp group implores FDA to regulate CBD, with acceptable guidelines, for consumer safety

Hemp advocates have been sending their own recommendations to the U.S. Food and Drug Administration to help direct the agency’s CBD working group in establishing an enforcement discretion policy for CBD products.

Another hemp group implores FDA to regulate CBD, with acceptable guidelines, for consumer safety is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs

From Another hemp group implores FDA to regulate CBD, with acceptable guidelines, for consumer safety on CBD Products & CBD Business News – Hemp Industry Daily.

This was autoposted by IFTTT. To find out more, read my post about news articles.

Republished by Plato

Published

on

CBD

CBD News: Italy suspends decree that added CBD preparations to narcotics law

Italy’s Health Ministry has backtracked on its decision to add ingestible, hemp-derived CBD formulas to a list of medicines in its narcotics law, issuing a decree to suspend the controversial change one day before it was due to take effect.

Italy suspends decree that added CBD preparations to narcotics law is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs

From Italy suspends decree that added CBD preparations to narcotics law on CBD Products & CBD Business News – Hemp Industry Daily.

This was autoposted by IFTTT. To find out more, read my post about news articles.

Republished by Plato

Published

on

Italy’s Health Ministry has backtracked on its decision to add ingestible, hemp-derived CBD formulas to a list of medicines in its narcotics law, issuing a decree to suspend the controversial change one day before it was due to take effect.

Italy suspends decree that added CBD preparations to narcotics law is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs

From Italy suspends decree that added CBD preparations to narcotics law on CBD Products & CBD Business News – Hemp Industry Daily.

This was autoposted by IFTTT. To find out more, read my post about news articles.

Source: http://blog.hempcbd.business/2020/10/cbd-news-italy-suspends-decree-that.html

Continue Reading

CBD

Hemptown USA Has Built A World Class Platform To Capitalize On The Booming Hemp Industry

In early 2021, we expect Hemptown USA to complete a go-public transaction and this is an opportunity that our readers should be aware of. We have been covering Hemptown since 2018 and are impressed with how the story has evolved during this time. In early 2017, Hemptown started to cultivate feminized hemp and is considered […]

The post Hemptown USA Has Built A World Class Platform To Capitalize On The Booming Hemp Industry appeared first on Technical420.

Republished by Plato

Published

on

In early 2021, we expect Hemptown USA to complete a go-public transaction and this is an opportunity that our readers should be aware of. We have been covering Hemptown since 2018 and are impressed with how the story has evolved during this time.

In early 2017, Hemptown started to cultivate feminized hemp and is considered to be a leading player in the cannabigerol (CBG) market. When we first met with Hemptown’s management team, the company was one of the few businesses to be focused on CBG and we are favorable on this focus.

Hemptown’s management team has a proven track record of success and is comprised of executives that previously worked at Fortune 500 companies (Intel and Kelloggs). We are favorable on how the management team has been able to make Hemptown standout in what has become a saturated market.

Positioned to Capitalize on the Current Market Environment

One of the reasons we are favorable on the opportunity is related to the infrastructure that has been put in place. Currently, Hemptown’s state-of-the-art FDA registered and cGMP certified facility is operating at 30% capacity and we expect this percentage to increase in 2021. Many of the company’s competitors are running out of capital and we have seen several CBD and CBG companies file for bankruptcy.

Last year, Hemptown raised $24 million through a series of private placements and has been cutting costs to conserve capital. This has left the business in a strong position to execute and we expect the company to record strong revenue growth as it ramps up capacity.

Another reason we are excited about Hemptown is related to how the business has evolved. The company has launched a line of hemp cigarettes that do not contain any nicotine and are made with CBD and CBG that is from its Oregon farm.

We have considered the hemp cigarette vertical to be an attractive market and are favorable on how Hemptown has differentiated its product line from what is currently available on the market. The products include a proprietary terpene infused filter that is available in a variety of flavors and we are favorable on this aspect of the story.

In a report from Cowen and Company, the US hemp industry is expected to be a $16 billion market by 2025. The passing of the 2018 US Farm Bill was a major catalyst for the cannabinoid market as it opened the door for an era of CBD commoditization. Following the passing of the bill, major retailers like Walgreens and CVS have entered the industry.

The surge of interest in the CBD market led to an even larger increase in the amount of production that companies had in place. This put substantial pressure on the price of CBD and high-profile operators like GenCanna (backed by Mitch McConnell) were forced to file for bankruptcy.

By being focused on multiple cannabinoids and by conserving cash, Hemptown has been able to survive the current market environment. We expect this aspect of the story to play an important role in how the business continues to grow and believe that Hemptown  is an operator to be aware of.

We believe that the next phase of growth for the market will be related to a surge in interest in cannabinoids like CBG, cannabichromene (CBC) and cannabidivarin (CBDV). We believe that Hemptown is positioned to be a beneficiary of this growth and will monitor how the story continues to evolve.

Executing on a Multi-Faceted Growth Strategy

Last year, Hemptown acquired Kirkman which is an established brand that has been in business for more than 70 years. Kirkman operates out of a facility that is FDA licensed and cGMP certified. When the acquisition was reported, we became increasingly excited about the opportunity and believe that Kirkland has played a key role how Hemptown has launched products.

By using state-of-the-art equipment for precision dosing, Hemptown has been able to create a diverse product line that includes tinctures, capsules, creams, topicals, gums, and edibles. The focus on being vertically integrated could increase margins by up to 20x and we are bullish on the impact that the facility has had on the economics of the business.

On top of selling its own product line, Hemptown offers white label products and we are favorable on the structure of the business. These products use premium cannabinoids and are fully traceable from seed-to-bottle. Hemptown’s white label platform is a full service offering that includes branding, fulfillment, and marketing services.

By operating a business model that has diversified revenue streams, Hemtown has been able to protect itself from decreasing CBD prices. The business model is based on margins and this is a key metric to be focused on. The strategy allows Hemptown to monetize inventory in multiple channels that are based on the demand and margins.

The saturation of the CBD market has substantially raised the cost of the end-consumer. Hemptown’s ability to sell to businesses and to consumers has protected margins while also being able to scale revenue. We believe that the strategy will allow Hemptown to efficiently monetize inventory and will monitor how the management is able to execute on this.

Focused on the International Opportunity

Another major potential growth driver for Hemptown is the expansion into the European Union (EU). Hemptown is pursuing a FSA license in the United Kingdom for its CBD and CBG products as well as bulk ingredients. The opportunity in the EU is massive and this is a market that we have been bullish on for several years.

Currently, Hemptown is in advanced discussions to partner with an established European supply chain that will provide it with the opportunity to move over 1,000 kilograms of CBD per month. We are favorable on the potential revenue that is associated with the relationship and will monitor how the company is able to capitalize on the EU market.

A Private Opportunity to be Aware of

Hemptown has attractive growth prospects and plans to make additional acquisitions to scale the business. The management has used a series of organic and inorganic growth initiatives to bring the business to where it is today.

We are favorable on the types of acquisitions that Hemptown has made and expect an additional acquisition to immediately prove to be accretive. We have faith in the management team’s ability to identify a business that would be complementary to the existing assets in place and are bullish on the potential impact it would have.

In early 2021, Hemptown plans to go public and this is an opportunity that we are closely following. If you are interested in learning more about Hemptown, please send an email to support@technical420.com with the subject “Hemptown” to be added to our distribution list.

Share Share - Facebook Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Source: https://technical420.com/cannabis-article/hemptown-usa-has-built-a-world-class-platform-to-capitalize-on-the-booming-hemp-industry/

Continue Reading

CBD

CBD for Fibromyalgia: Can CBD Really Help?

According to the CDC, roughly 4 million US adults are affected by fibromyalgia. Although researchers don’t fully understand the cause of fibromyalgia, there are means of treatment available. The unknowns of this condition have left many people asking the question: can CBD help with fibromyalgia? This question should come as no surprise considering that research… View Article

The post CBD for Fibromyalgia: Can CBD Really Help? appeared first on The CBD Insider.

Republished by Plato

Published

on

cbd for fibromyalgia

According to the CDC, roughly 4 million US adults are affected by fibromyalgia. Although researchers don’t fully understand the cause of fibromyalgia, there are means of treatment available. The unknowns of this condition have left many people asking the question: can CBD help with fibromyalgia?

This question should come as no surprise considering that research indicates CBD may alleviate the most common fibromyalgia symptoms, which the CDC reports as:

  • Pain and stiffness
  • Fatigue
  • Depression
  • Anxiety
  • Sleep problems
  • Cognitive issues
  • Headaches/migraines

If you’re remotely familiar with CBD, you likely recognize an overlap between its potential benefits and these common fibromyalgia symptoms.

CBD for Fibromyalgia: Table of Contents

  1. A Look into the Research of CBD for Fibromyalgia
  2. Other Potential Benefits of CBD
  3. What is CBD?
  4. CBD Risks and Side Effects
  5. Conclusion

A Look into the Research of CBD for Fibromyalgia

Current research on the potential of CBD for fibromyalgia relief is severely limited. However, the results of the few studies that have been conducted show enough evidence for scientists to continue studying this subject.

Journal of Clinical Medicine 2019: Cannabis and Fibromyalgia

In a 2019 study published by the Journal of Clinical Medicine, researchers observed several hundred participants diagnosed with fibromyalgia for a minimum of six months. Since women are twice as likely to develop fibromyalgia as men, 82% of participants were female.

This study explored the benefits medical cannabis may provide for patients diagnosed with fibromyalgia. Although the medical cannabis used in the study contained both THC and CBD, the results provided a view into how cannabinoids may play a role in alleviating fibromyalgia symptoms.

Participants were initially given a low dose of medical cannabis. Over the course of six months, researchers titrated the dosage given to participants. The average starting dosage was 670mg/day, and by the six-month mark, the average medical cannabis dosage was 1,000mg/day. This resulted in participants being exposed to a daily average of 140mg of THC and 39mg of CBD.

This study did not come without a few limitations. Researchers stated that “this study was observational in nature and could not establish causality between medical cannabis use and improvement in fibromyalgia outcomes.” In other words, they were unable to definitively state that observed results were directly due to participants using medical cannabis because the study was neither randomized nor controlled.

Secondly, researchers faced issues with participants who were unwilling to follow-up after the initial six-month trial period. A 30% non-respondent rate was reported, which may have resulted in a non-response bias.

Lastly, the study was designed to incorporate 14 various medical cannabis strains. According to researchers, “this prevented [researchers] from conducting a comparison between THC and CBD strains and products in terms of effectiveness and safety.”

Limitations aside, the data collected was still grounds for researchers to deem medical cannabis a potentially “effective and safe treatment to fibromyalgia.” Additionally, the results of this study “highlight the need for further research.”

Overall, 52.5% of the study participants initially reported their pain level as “high”; however, after six months of treatment, the number of participants reporting “high” levels of pain was reduced to 7.9%.

International Association for the Study of Pain 2019: THC, CBD and Fibromyalgia

In a similar but much smaller study (n=20) published by the Journal of International Association for the Study of Pain, researchers explored medical cannabis use in fibromyalgia cases. This study varied from the aforementioned research by documenting how various THC:CBD ratios affected patient outcomes.

Participants were provided with four variations of medical cannabis. These variations included a placebo dose (containing no THC or CBD), a dose containing both high THC and CBD, a low THC/high CBD dose, and a high THC/low CBD dose.

The results of the study revealed that high CBD/low THC products were not successful in alleviating fibromyalgia pain. However, those using high THC/low CBD products reported a notable improvement in their pressure/pain threshold.

Here is where things get interesting for CBD. Although the high CBD/low THC products proved ineffective, 90% of participants reported a 30% improvement in spontaneous pain when using a product containing high concentrations of both CBD and THC.

Overall, researchers concluded that more research is required to understand the complexities of THC/CBD’s role in pain reduction though early evidence shows CBD alone may not be effective in treating fibromyalgia pain. That said, it is important to remember that this was a relatively small study and certainly not comprehensive evidence. 

Other Potential Benefits of CBD 

The growing list of potential CBD benefits makes this naturally occurring, non-intoxicating cannabinoid seem too good to be true at first glance, but results from studies around the world are beginning to back up some of these claims.

Many of the benefits touted by CBD users are only supported by anecdotal evidence at this time. That said, the amount of positive user experiences, like many of those reported in our 2019 US CBD Consumer Report, has garnered the attention of researchers worldwide.

In our survey of over 1,000 individuals, users reported the following regarding their experience with CBD:

  • 82.4% of those using CBD for energy reported CBD being very or extremely effective for increasing energy
  • 79.5% of those using CBD for mood reported CBD being very or extremely effective for mood regulation
  • 78.9% of those using CBD for relaxation reported CBD being very or extremely effective for relaxation
  • 76.8% of those using CBD for sleep reported CBD being very or extremely effective in helping them sleep
  • 67.4% of those using CBD for aches/discomfort reported CBD being very or extremely effective in providing relief from aches/discomfort

If we look at the controlled study results currently available, we can see additional reason to believe CBD has a lot of potential.

In a study published in the Brazilian Journal of Psychiatry, researchers concluded that “CBD seems to produce its anxiolytic effects through receptors in the serotonergic system.” If you suffer from anxiety, you should check out our article that takes a deep-dive into using CBD for relief.

Another use case that has captured the attention of many is CBD’s potential to provide pain relief. Numerous studies have explored CBD as a pain treatment option with promising results. If you suffer from pain or have found yourself reaching for opioids, we recommend checking out our comprehensive piece on CBD’s potential to alleviate pain.   

What is CBD?

Cannabidiol or CBD is a naturally occurring compound produced by the cannabis plant. This cannabinoid is closely related to THC; however, CBD does not produce any intoxicating or psychoactive effects.

CBD’s non-addictive and non-habit forming properties, a growing list of potential benefits, and removal from the DEA’s controlled substances list are all contributing factors to its rapid rise in popularity.

CBD is widely available in most retailers around the nation. Manufacturers have created a litany of CBD products for consumers to choose from. Currently, CBD-infused product offerings include tinctures, vapes, edibles, patches, capsules, creams, smokable flower, and much more. 

CBD Risks and Side Effects 

Like most things, users should be informed of the potential side effects and risks associated with CBD use.

Contraindications

CBD users who also use or plan on using other OTC or Rx medications should discuss the potential for interactions with their medical provider.

CBD utilizes the Cytochrome P450 enzyme which is produced by the liver. This enzyme is responsible for metabolizing or breaking down CBD into a form that our bodies can use.

The potential for contraindications may surface when a CBD user takes another medication that also utilizes CYP enzymes in order to reach systemic circulation. An estimated 70-80% of modern medications rely on CYP enzymes.

Side Effects

CBD is commonly thought of as free of side effects, but this isn’t entirely true. Reports of side effects associated with CBD are generally deemed mild.

In a study published by the Journal of Cannabis and Cannabinoid Research, the most commonly reported side effects associated with CBD use include sleepiness, changes in appetite/weight, and diarrhea.

That said, the same study also comments, “in comparison with other drugs, used for treatment of these medical conditions, CBD has a better side effect profile.” [13]

Limited Research

Although there are currently over 300 clinical trials underway involving CBD, there is limited information that has already been published.

This is due in part to CBD’s rapid rise in popularity coupled with the removal of many regulatory hurdles with the passing of the 2018 Farm Bill.

All current and potential CBD users should remember that a lot of evidence behind CBD’s potential is anecdotal. This isn’t intended to discourage users from trying CBD but instead, to serve as a reminder that just because CBD works for one person, doesn’t necessarily mean it will work for everyone. Hopefully, as more research becomes available, scientists will develop a better understanding of CBD’s mechanisms of action.

Is My CBD Product High-Quality? 

It probably comes as no surprise that, like most industries, there are some shady brands in the CBD space. Without additional regulation, the burden remains on the individual to ensure they’re using a high-quality CBD product from a reputable brand.

We recognize the headache this can be for many users. That’s what led us to create our CBD Knowledge Center. This free resource is filled with countless tips and guides to help you get the most out of your CBD purchases.

Additionally, we’ve implemented a Trusted Brands tool. This is a free tool where users can compare the pros and cons of CBD brands that we’ve thoroughly vetted for quality.

If you’re looking for a tip, we recommend checking for your product’s certificate of analysis (COA). COAs are documents provided to brands by third-party labs. COAs provide information regarding your product’s contents as well as the presence of potential toxins (heavy metals, pesticides, mold, etc.).

Every CBD product should have a matching COA available. If you’re unable to find a COA for your product on the brand’s website or if they’re unwilling to provide a copy of the COA, this is a major red flag and a reason to find a new CBD brand.

Another thing that all CBD users should check for is proper labeling. If the information on your product’s label seems vague or there appears to be a lot of room for interpretation regarding contents, dosage, or directions, we recommend reaching out to the brand through their website or social media for further clarification.

Overall, users should remember that a reputable CBD brand will always be happy to provide a COA for any of their products and discuss any questions you may have.

Conclusion 

Preliminary research presents a mixed bag in terms of CBD’s ability to provide relief from fibromyalgia symptoms. With the hundreds of CBD-based clinical trials in progress, we suspect researchers will be able to provide a more definitive answer into CBD’s potential to help those suffering from fibromyalgia.

If you are currently battling fibromyalgia and want to try CBD, we recommend first speaking with your medical provider to develop a monitoring plan and discuss any changes to keep an eye out for.

We also recommend signing up for our free newsletter. This is a great resource for the latest CBD news, research findings, and product reviews.

The CBD Insider Editorial Team

The mission of The CBD Insider is to provide consumers with a way to find high-quality, safe, and well-formulated CBD products. Our editorial team of passionate industry professionals achieves this mission by providing unbiased, trustworthy, and well-researched reporting about the CBD industry.

Source: https://thecbdinsider.com/knowledge-center/cbd-for-fibromyalgia-can-cbd-really-help/

Continue Reading
CBD4 days ago

The New Italian Cannabis Contradiction

Heartland4 days ago

Bought Haven St. 150 peace tea. Looking for a review before I brew myself a cup

CBD1 day ago

Will Europe THC Limit Increase to 0.3%?

News4 days ago

Sugarbud Announces Supply Agreement with British Columbia Liquor Distribution Branch

Heartland4 days ago

Who Is Newly Lobbying On Cannabis?

Heartland4 days ago

Dosage recommendation and does it make anyone else feel groggy all day?

Heartland4 days ago

CBD vs CBN: What’s The Actual Difference?

Heartland5 days ago

CBD Skin Care Products Market Size 2020 By Product Types, End-Users, Regional Outlook …

Heartland5 days ago

Terp Town

Heartland4 days ago

Vaping CBD flower doesn’t really do anything. Can you vape hash? Is my flower just too weak?

News4 days ago

FluroTech Announces Filing of Patent Applications With Respect to Its Proprietary Diagnostic Test Method and Pandemic Defense Platform

News4 days ago

Rubicon Organics Establishes Route to Market for Cannabis 2.0 Products

Heartland4 days ago

CBD flower and hair testing?

Heartland4 days ago

What cbd cartridge brand is the best?

Heartland4 days ago

CBG for Crohn’s

Heartland3 days ago

Accountants from Coast to Coast Meet to Discuss Cannabis Issues

Heartland5 days ago

Researchers Report CBD Appears To Help Reduce Lung Damage From COVID

Material5 days ago

Kinetic modeling of the leaching of LiCoO2 with phosphoric acid

Heartland5 days ago

Global Cannabidiol Oil (CBD Oil) Market Data Analysis 2020-2026: Whistler, CBD American …

Heartland4 days ago

Canada’s Stubborn Black-Market Cannabis Problem

Heartland4 days ago

Cannabis Tycoon Curaleaf expected to monetize loads after Connecticut Legalizes

News4 days ago

Canada House Wellness Group Enters into Distribution Agreement for Cannabis 2.0 Products

News4 days ago

Canntab to Launch in Australia and Participate in Australia’s Largest Cannabis Research Study

Heartland4 days ago

MMJ Recs Medical Marijuana Cards And Your Privacy: Are MMJ Cards Confidential?

Heartland4 days ago

Exclusive: Colorado’s Governor Jared Polis Talks Legal Cannabis

Heartland4 days ago

CBD Hemp Oil Market Research Report Covers – Product Types, Applications, Market Share …

Heartland4 days ago

Is this site legit, or no?

News3 days ago

EBV Elektronik adds NanoXplore to its linecard

Material5 days ago

Study of HVOF-sprayed hydroxyapatite/titania graded coatings under in-vitro conditions

Material5 days ago

Experimental investigation on partition controllable induction heating-hot stamping process of high-strength boron alloyed steel plates with designable temperature patterns

Trending

A Cloud Nine Capital Entity Copyright © 2020 – All Rights Reserved Proudly Made in America